Erythropoietin induces tumour progression and CD39 expression on immune cells in a preclinical model of triple‐negative breast cancer
Immunology · 2024
DOI: 10.1111/imm.13832 ↗Kurz gefasst
Fachartikel in der Zeitschrift Immunology, 2024. Verfasst von Stéphanie Bessoles und 5 weiteren Autor:innen. Beteiligte Einrichtung: Université Paris Cité, CNRS, INSERM, UTCBS, Unité des Technologies Chimiques et Biologiques pour la Santé, Paris, France. Hauptthemen laut MEDLINE: Antigens, CD, Apyrase, Erythropoietin, Triple Negative Breast Neoplasms. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 88 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Groupement des Entreprises Françaises dans la lutte contre le Cancer, Ligue Contre le Cancer.
Abstract (Originalsprache)
The adverse effects observed in some cancer patients treated with erythropoiesis‐stimulating agents such as erythropoietin (EPO) might be due to the latter's well‐known immunosuppressive functions. Here, we used a mouse model of syngeneic triple‐negative breast cancer to explore EPO's immunomodulatory role in a tumour setting. Our results showed that EPO treatment promotes tumour growth, exacerbates the ‘immune desert’, and results in a ‘cold tumour’. EPO treatment changed the immune cell distribution in peripheral blood, secondary lymphoid organs, and the tumour microenvironment (TME). Our in‐depth analysis showed that EPO mainly impacts CD4 T cells by accelerating their activation in the spleen and thus their subsequent exhaustion in the TME. This process is accompanied by a general elevation of CD39 expression by several immune cells (notably CD4 T cells in the tumour and spleen), which promotes an immunosuppressive TME. Lastly, we identified a highly immunosuppressive CD39 + regulatory T cell population (ICOS + , CTLA4 + , Ki67 + ) as a potential biomarker of the risk of EPO‐induced tumour progression. EPO displays pleiotropic immunosuppressive functions and enhances mammary tumour progression in mice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Université Paris Cité, CNRS, INSERM, UTCBS, Unité des Technologies Chimiques et Biologiques pour la Santé, Paris, France.
- Clinical Immunology Laboratory, Groupe Hospitalier Universitaire Paris-Sud, Hôpital Kremlin-Bicêtre, Assistance Publique-Hôpitaux de Paris, Le-Kremlin-Bicêtre, France.
- GenoSplice Technology, Paris, France.
ORCID-Profile: Stéphanie Bessoles
Förderung
- Groupement des Entreprises Françaises dans la lutte contre le Cancer
- Ligue Contre le Cancer
Zitieren
APA
Bessoles, S., Chiron, A., Sarrabayrouse, G., De La Grange, P., Abina, A. M., & Hacein-Bey-Abina, S. (2024). Erythropoietin induces tumour progression and CD39 expression on immune cells in a preclinical model of triple‐negative breast cancer. Immunology. https://doi.org/10.1111/imm.13832
Vancouver
Bessoles S, Chiron A, Sarrabayrouse G, De La Grange P, Abina AM, Hacein-Bey-Abina S. Erythropoietin induces tumour progression and CD39 expression on immune cells in a preclinical model of triple‐negative breast cancer. Immunology. 2024. doi:10.1111/imm.13832
BibTeX
@article{Bessoles2024,
author = {Bessoles, Stéphanie and Chiron, Andrada and Sarrabayrouse, Guillaume and De La Grange, Pierre and Abina, Amine M and Hacein-Bey-Abina, Salima},
title = {Erythropoietin induces tumour progression and CD39 expression on immune cells in a preclinical model of triple‐negative breast cancer},
journal = {Immunology},
year = {2024},
doi = {10.1111/imm.13832}
}
EUVIMED